

Reference

Hahn A, Moeller S, Schlausch A, Ekmann M, de Chelle G, Westerlund M, Braatz F, Mayr W.

Ottobock Healthcare Products GmbH, Brehmstrasse 16, AT-1110 Vienna

Effects of a full-body electrostimulation garment application in a cohort of subjects with cerebral palsy, multiple sclerosis, and stroke on upper motor neuron syndrome symptoms

Biomedical Engineering / Biomedizinische Technik; DOI:10.1515/bmt-2023-0271

Products

EXOPULSE Mollii Suit

Major Findings

With EXOPULSE Mollii Suit:

→ **Positive effects on static and dynamic balance, fall risk, mobility, health utility, upper extremity function** (for subjects with Berg Balance Score <45 at baseline)


→ **Overall reduction in spasticity related pain after 4 weeks** (for subjects reporting pain at Baseline)

- Cerebral Palsy (CP): - 35.8%
- Multiple Sclerosis (MS): - 26.5%
- Stroke: - 29.1%

→ **Functional and clinical improvements (effect size Cohen's d)*:**

| | CP | MS | Stroke |
|------------------------------------|-------------|-------------|-------------|
| Berg Balance Scale (BBS) | 1.64 | 1.83 | 1.28 |
| Functional Gait Assessment | 1.59 | 1.28 | 0.89 |
| 10m walk test | 0.76 | 1.07 | 0.92 |
| Wolf Motor Function Test | 1.00 | 0.93 | 0.71 |
| Timed Up and Go | 0.29 | 0.83 | 0.78 |
| EQ 5D 5L | 0.50 | 1.11 | 1.26 |
| Pain (Subscale of EQ 5D 5L) | 1.28 | 0.78 | 0.78 |

* *Small effect size < 0.3; medium effect size = 0.3-0.8; large effect size > 0.8*



| Population | | All subjects | BBS < 45 at baseline |
|------------|--|---|---|
| Subjects: | | 72 (44 female, 28 male) | 44 (24 female, 20 male) |
| Etiology: | | CP (N = 29) MS (N = 23) Stroke (N = 20) | CP (N = 16) MS (N = 16) Stroke (N = 12) |
| Mean age: | | 36.64 ± 19.8 years | 39.16 ± 19.9 years |
| GMFCS: | | 1-3 | 1-3 |

Study Design

Observational study:



¹The suit (without stimulation); In case any aid (primarily orthotics) was used by participants during daily living, they were worn also during all assessments.

²Use of the suit for 60 minutes daily or every other day during the entire trial period and no change of lifestyle, routine or other applied medical interventions, e.g. physical therapy, should be made during their participation in the study.

For six outcome measures the recorded data were stratified by etiology (CP, MS, Stroke) and a Berg Balance Score <45 at baseline. The results of the pain subscale of EQ 5D 5L were stratified by etiology (CP, MS, Stroke) and subjects reporting pain at baseline. The effect sizes (Cohen's d) were classified as "large" if $d \geq 0.8$.

Results

| Body Functions | | | Activity | | | | Participation | Environment | Others |
|---------------------|---------------------------|-------|--------------------------|--------------------------|--------|--------------------------|-------------------------------|------------------|-------------------|
| Biomechanical (ROM) | Medical (Pain / Injuries) | Other | Upper extremity function | Lower extremity function | Safety | Activity, Mobility, ADLs | Preference, Satisfaction, QoL | Health Economics | Technical aspects |

| Category | Outcomes | | Results for Baseline vs EXOPULSE Mollii Suit | | | | Sig.* |
|---------------------------|-----------------------------|--------|--|-------------|--------------|------------------------|-------|
| | | | Base-line (T0) | 60 min (T1) | 4 weeks (T2) | Effect size (T0 vs T2) | |
| Medical (Pain / Injuries) | Pain (Subscale of EQ 5D 5L) | CP | 2.79 | 2.22 | 1.79 | 1.28 | *** |
| | | MS | 3.06 | 2.00 | 2.25 | 0.78 | ** |
| | | Stroke | 2.58 | 1.83 | 1.83 | 0.78 | * |
| Upper extremity function | Wolf Motor Function Test | CP | 53.1 | 56.1 | 59.1 | 1.00 | *** |
| | | MS | 64.2 | 71.7 | 71.7 | 0.93 | * |
| | | Stroke | 28.6 | 30.6 | 38.3 | 0.71 | + |
| Lower extremity function | Functional Gait Assessment | CP | 11.0 | 15.5 | 16.6 | 1.59 | *** |
| | | MS | 11.3 | 16.7 | 18.3 | 1.28 | ** |

| Category | Outcomes | Results for Baseline vs EXOPULSE Mollii Suit | | | | Effect size (T0 vs T2) | Sig.* |
|-----------------|---------------------|--|----------------|-------------|--------------|------------------------|-------|
| | | | Base-line (T0) | 60 min (T1) | 4 weeks (T2) | | |
| | | Stroke | 14.17 | 16.5 | 19.0 | 0.89 | + |
| | 10m walk test [m/s] | CP | 0.96 | 1.0 | 1.1 | 0.76 | + |
| | | MS | 0.66 | 0.76 | 0.8 | 1.07 | *** |
| | | Stroke | 0.57 | 0.67 | 0.76 | 0.92 | ** |
| Safety | Berg Balance Scale | CP | 31.0 | 36.3 | 39.1 | 1.64 | *** |
| | | MS | 27.8 | 34.1 | 38.1 | 1.83 | *** |
| | | Stroke | 34.7 | 40.8 | 41.6 | 1.28 | ** |
| | Timed Up and Go [s] | CP | 26.4 | 22.0 | 23.2 | 0.29 | * |
| | | MS | 29.7 | 23.3 | 21.3 | 0.83 | *** |
| | | Stroke | 36.0 | 25.7 | 22.3 | 0.78 | ** |
| Quality of life | EQ 5D 5L | CP | 0.76 | 0.87 | 0.87 | 0.5 | * |
| | | MS | 0.55 | 0.77 | 0.73 | 1.11 | ** |
| | | Stroke | 0.54 | 0.66 | 0.75 | 1.26 | * |

* no difference (0), positive trend (+), negative trend (-), significant (*: p<0.5, **: p<0.01, ***: p<0.001), not applicable (n.a.)

Effect size Cohen's d: *Small effect size < 0.3; medium effect size = 0.3-0.8; large effect size > 0.8*

Author's Conclusion

"Individualized multi-site transcutaneous electrical stimulation seems to increase ambulation-related skills in subjects with upper motor neuron syndrome stemming from infantile cerebral palsy, multiple sclerosis and stroke. These results obtained with an improved full-body electrostimulation garment show encouraging effects on static and dynamic balance, fall risk and mobility. Upper extremity improvement may be observed as well as an overall increase in health utility and a reduction in spasticity-related pain. Effects are immediate (after one hour of stimulation) as well as sustained (1 month of application) with stimulation applied for 60 minutes daily or every other day. Outcomes being sensitive to such improvements could be identified. The results may improve the quality of individual trial fittings as well as inform controlled trials that are most clearly warranted in this context." (Hahn, not yet published)

© 2023, Otto Bock HealthCare Products GmbH ("Otto Bock"), All Rights Reserved. This article contains copyrighted material. Wherever possible we give full recognition to the authors. We believe this constitutes a 'fair use' of any such copyrighted material according to Title 17 U.S.C. Section 107 of US Copyright Law. If you wish to use copyrighted material from this site for purposes of your own that go beyond 'fair use', you must obtain permission from the copyright owner. All trademarks, copyrights, or other intellectual property used or referenced herein are the property of their respective owners. The information presented here is in summary form only and intended to provide broad knowledge of products offered. You should consult your physician before purchasing any product(s). Otto Bock disclaims any liability related from medical decisions made based on this article summary.